Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Jang, Joung-Soon | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Rho, Myung Hwan | - |
dc.contributor.author | Lee, Suee | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Nam, Eun Mi | - |
dc.contributor.author | Lee, Hyo Rak | - |
dc.contributor.author | Jun, Hyun Jung | - |
dc.contributor.author | Chi, Kyong-Choun | - |
dc.date.available | 2019-03-08T17:40:19Z | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.issn | 1432-0843 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9685 | - |
dc.description.abstract | We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy. Patients treated with gemcitabine-based palliative treatment were enrolled in this study. Patients were received modified FOLFOX3 (mFOLFOX3) consists of oxaliplatin 85 mg/m(2) (day 1) and leucovorin 30 mg (days 1, 2) followed by 5-fluorouracil 1,500 mg/m(2) (days 1, 2) every 2 weeks. Between March 2010 and June 2012, a total of 30 patients were enrolled in this study. Twenty-eight patients were measurable for treatment response. One achieved complete response, and one a partial response was observed. Overall response rate was 7.1 % (95 % confidence interval 0.9-23.5 %). The median progression-free survival was 1.6 months, and the median overall survival was 4.4 months. Grade 3-4 hematologic toxicities included neutropenia (6.7 %) and thrombocytopenia (3.4 %). The most common non-hematologic toxicity was neuropathy (22.2 %). However, the most common grade 3-4 non-hematologic toxicity was hyperbilirubinemia (5.0 %). There was one treatment-related death due to neutropenic infection. mFOLFOX3 as a second-line regimen has modest effect and tolerable toxicity in unresectable/metastatic biliary tract cancer patients who have been treated previously via gemcitabine-based chemotherapy. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00280-015-2691-1 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.75, no.4, pp 757 - 762 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000351549100011 | - |
dc.identifier.scopusid | 2-s2.0-84925501172 | - |
dc.citation.endPage | 762 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 757 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 75 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Biliary tract cancer | - |
dc.subject.keywordAuthor | Second line | - |
dc.subject.keywordAuthor | Fluorouracil | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.